Sponsor:
Bambusa Therapeutics
Code:
NCT06808477
Conditions
Atopic Dermatitis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Accepted
Interventions
BBT001
Placebo
Brief summary:
Conditions
Atopic Dermatitis
Study ID
NCT06808477
Start date
Feb 27, 2025
Status verified date
Jul, 2026
Completion date
Feb 28, 2027
Anticipated
Primary completion date
Feb 28, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Accepted
Enrollment
237 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Part A Single Ascending Dose BBT001
experimental: Part B Multiple Ascending Dose BBT001
experimental: Part C Multiple Ascending Dose BBT001
placebo comparator: Part A Single Ascending Dose Placebo
placebo comparator: Part B Multiple Ascending Dose Placebo
placebo comparator: Part C Multiple Ascending Dose Placebo
active comparator: Part D Single Ascending Dose BBT001
placebo comparator: Part D Single Ascending Dose Placebo
active comparator: Part E Multiple Ascending Dose BBT001 - Dose Level 1
placebo comparator: Part E Multiple Ascending Dose Placebo
active comparator: Part E Multiple Ascending Dose BBT001 - Dose Level 2
Interventions
BBT001
Placebo
Primary outcome measure
Central contacts
Locations
First OC Dermatology
Recruiting
Irvine, California, United States, 92614
OptiSkin Medical
Recruiting
New York, New York, United States, 10128
Equity Medical, LLC
Recruiting
The Bronx, New York, United States, 10455
Sponsor
Bambusa Therapeutics
Last update posted
Aug 13, 2026
Last verified
Jul, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Bambusa Therapeutics on 2026-08-13.